Insider buying last 90 days
No open-market insider purchases were filed for DOCS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
This week's news on Doximity centers on a wave of securities class action lawsuit reminders, with multiple law firms, including Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, Kaplan Fox, Rosen Law Firm, and SBS Law, pointing investors toward a November 16, 2026 lead plaintiff deadline. The underlying claims concern alleged misrepresentations between August 8, 2024 and May 13, 2026 about revenue growth, market share, the Newsfeed product's impact, decelerating sales, contracting net income, and shifts in pharmaceutical advertising budget deployment.
Shares closed at $32.87, up 1.1%, sitting above both the 50-day average of $29.22 and the 200-day average of $25.32, with the 50-day above the 200-day. The GekkoIndex reads 54, placing the stock in the Neutral zone. Price stands 14.4% above Gekko Fair Value of $28.72. One-month return is 7.8%, three-month 25.9%, six-month 25.2%, while the one-year return remains negative at -47.5%.
The next earnings date falls on 4 February 2027, 86 days out and outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the recent windows. Seasonality data covering 5 years shows the next 20 trading days averaging an 11.1% return, with gains in 3 of those years. Analyst consensus among 13 firms includes 4 buy, 7 hold, and 2 sell ratings, with a consensus target of $31.11, implying -5.4% versus the current price.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Doximity scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $33.34 is above the 50-day ($29.73) and 200-day ($25.20) averages, and the 50-day is above the 200-day.
See the chart53.6, Neutral
Reading 53.6 is in the Neutral zone.
See the GekkoIndex17.1% above
Price is 17.1% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 81 days
Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.
See earnings−3.9% on average
From this point in the calendar, the next 20 trading days averaged −3.9% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Doximity closed at $33.34 on Nov 13, 2026, −34.6% over the past year, inside a 52-week range of $17.15 to $51.85.
Use the left and right arrow keys to read daily values.
Put DOCS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Doximity runs a cloud-based digital platform built for healthcare practitioners across the United States. Members use it to connect with fellow professionals, coordinate patient care, hold remote consultations, keep up with medical news and research, and support their career development. The platform is best known as a networking and productivity hub for doctors and other clinicians.
The company draws its business primarily from pharmaceutical companies and healthcare organizations, which make up its main customer base. This positions Doximity as a service provider to institutions within medicine rather than a direct-to-consumer product, with its tools built around the daily needs of practicing clinicians.
Doximity was founded in 2010, originally under the name 3MD Communications, Inc., before adopting its current name later that same year. The company is headquartered in San Francisco, California. Its shares are listed on the NYSE under the ticker DOCS.
Doximity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.6, in the Neutral zone, down 0.4 points over five sessions.
Down 0.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 70 | −1.5% | −0.7% |
| Accumulation | 202 | +1.0% | −2.0% |
| Neutral (current zone) | 380 | +0.7% | +4.8% |
| Distribution | 39 | +0.2% | −2.4% |
| Selling | 11 | −6.2% | −8.7% |
Average DOCS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Doximity trades 17.1% above Gekko Fair Value of $28.47, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Doximity shares are worth, recalculated every trading day.
$28.47
Gekko Fair Value, Nov 14, 2026
17.1% Overvalued
At the end of Aug 2026 the price was 3.8% below the estimate.
No open-market insider purchases were filed for Doximity, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for DOCS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in DOCS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Doximity has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds DOCS.
Doximity reports on Feb 4, 2027, after the close (81 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 4, 2027
Expected after the close, 81 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.14 est $0.16 | $156.6M est $151.8M | +26.6% |
| May 13, 2026 | $0.26 est $0.28 | $145.4M est $144.0M | −31.9% |
| Feb 5, 2026 | $0.46 est $0.45 | $185.1M est $181.6M | −21.3% |
| Nov 6, 2025 | $0.45 est $0.38 | $168.5M est $157.9M | −15.2% |
| Aug 7, 2025 | $0.36 est $0.30 | $145.9M est $139.5M | +14.5% |
| May 15, 2025 | $0.38 est $0.27 | $138.3M est $133.7M | −11.7% |
| Feb 6, 2025 | $0.45 est $0.31 | $168.6M est $134.1M | +36.3% |
| Nov 7, 2024 | $0.30 est $0.25 | $136.8M est $127.1M | +37.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Doximity is $31.50, −5.5% from the last close, from 13 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 13 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Barclays | $30 | −10.0% |
| Nov 10 | Barclays | $30 | −10.0% |
| Nov 9 | Morgan Stanley | $35 | +5.0% |
| Nov 9 | Canaccord Genuity | $40 | +20.0% |
| Nov 8 | BTIG | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Doximity averaged −3.9% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −5.0% | 2 of 5 |
| Next 10 trading days | −0.5% | 3 of 5 |
| Next 15 trading days | −2.3% | 2 of 5 |
| Next 20 trading days | −3.9% | 1 of 5 |
| Next 30 trading days | −2.3% | 3 of 5 |
For scale, DOCS’s typical 20-trading-day move in either direction is about 10.6%.
Doximity’s market cap is $5.94B, with a P/E ratio of 46.1 and revenue of $661.6M over the last twelve months.
Coverage of Doximity this week reads negative: 0 positive, 0 neutral and 10 negative headlines.
Doximity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 10.6% above |
| PLTRPalantir Technologies | Accumulation | 8.2% below |
| ORCLOracle | Neutral | 27.9% below |
| PANWPalo Alto Networks | Accumulation | 0.6% above |
| CRWDCrowdStrike | Accumulation | 0.9% above |
| CRMSalesforce | Accumulation | 12.1% below |
A peer links to its own page where one exists.
Doximity’s market cap is $5.94B at the Nov 13, 2026 close of $33.34, with 127.5M shares outstanding. The shares trade on a P/E ratio of 46.1.
The consensus analyst 12-month price target for Doximity is $31.50, −5.5% from the last close. Of the 13 firms that rated the stock in the last 90 days, 4 rate it a buy, 7 a hold and 2 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Doximity is overvalued: the Nov 13, 2026 close of $33.34 is 17.1% above Gekko Fair Value of $28.47. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Doximity is expected to report on Feb 4, 2027, after the market closes (81 days away). Analysts expect earnings of $0.41 per share on revenue of $195.8M. Doximity beat the earnings estimate in 6 of its last 8 reports, moving 24.4% on average across the report.
Doximity’s 52-week high is $51.85 and its 52-week low is $17.15; it closed at $33.34 on Nov 13, 2026, −34.6% over the past year. Over the last five years the shares peaked at $85.21 on Feb 10, 2025.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.